Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment

Katayoun Djazayeri, Zoltán Szilvássy, Barna Peitl, József Németh, Laszlo Nagy, Attila Kiss, Boglárka Szabó, Ilona Benko

Research output: Contribution to journalArticle

Abstract

Our preliminary data indicate that rosiglitazone may be myeloprotective. We investigated whether it can modify bone marrow recovery. Five-day pre-treatment with rosiglitazone significantly accelerated recovery of 5-fluorouracil-damaged bone marrow in mice. Frequency and femoral content of granulocyte-macrophage progenitors reached mean baseline faster in pre-treated groups than in 5-fluorouracil-treated controls. Consequently, neutropenia was milder. Five-day insulin pre-treatment had similar effects in vivo. Insulin supports in vitro hematopoiesis. The observed myeloprotection demonstrated the importance of insulin in vivo. Clinical use of insulin to moderate myelotoxicity is impractical but rosiglitazone, an insulin sensitizer, could offer hope. Although rosiglitazone tends to increase plasma insulin levels, the significant myeloprotection was partly due to direct effects on progenitors. In vitro rosiglitazone enhanced the survival of both murine progenitor and human mobilized blood stem cells in the presence of 5-fluorouracil, the effect of which was neutralized by a peroxisome-proliferator-activated receptor-γ antagonist.

Original languageEnglish (US)
Pages (from-to)122-129
Number of pages8
JournalEuropean Journal of Pharmacology
Volume522
Issue number1-3
DOIs
StatePublished - Oct 17 2005
Externally publishedYes

Fingerprint

rosiglitazone
Fluorouracil
Bone Marrow
Insulin
Granulocyte-Macrophage Progenitor Cells
Peroxisome Proliferator-Activated Receptors
Hematopoiesis
Thigh
Neutropenia
Blood Cells
Stem Cells

Keywords

  • CFU-GM (Granulocyte-macrophage progenitor cell)
  • Insulin
  • Myeloprotection
  • Neutropenia
  • Rosiglitazone
  • Stem cell

ASJC Scopus subject areas

  • Pharmacology

Cite this

Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment. / Djazayeri, Katayoun; Szilvássy, Zoltán; Peitl, Barna; Németh, József; Nagy, Laszlo; Kiss, Attila; Szabó, Boglárka; Benko, Ilona.

In: European Journal of Pharmacology, Vol. 522, No. 1-3, 17.10.2005, p. 122-129.

Research output: Contribution to journalArticle

Djazayeri, K, Szilvássy, Z, Peitl, B, Németh, J, Nagy, L, Kiss, A, Szabó, B & Benko, I 2005, 'Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment', European Journal of Pharmacology, vol. 522, no. 1-3, pp. 122-129. https://doi.org/10.1016/j.ejphar.2005.08.053
Djazayeri, Katayoun ; Szilvássy, Zoltán ; Peitl, Barna ; Németh, József ; Nagy, Laszlo ; Kiss, Attila ; Szabó, Boglárka ; Benko, Ilona. / Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment. In: European Journal of Pharmacology. 2005 ; Vol. 522, No. 1-3. pp. 122-129.
@article{ee3a172951c74bd8980b7dcda7925efa,
title = "Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment",
abstract = "Our preliminary data indicate that rosiglitazone may be myeloprotective. We investigated whether it can modify bone marrow recovery. Five-day pre-treatment with rosiglitazone significantly accelerated recovery of 5-fluorouracil-damaged bone marrow in mice. Frequency and femoral content of granulocyte-macrophage progenitors reached mean baseline faster in pre-treated groups than in 5-fluorouracil-treated controls. Consequently, neutropenia was milder. Five-day insulin pre-treatment had similar effects in vivo. Insulin supports in vitro hematopoiesis. The observed myeloprotection demonstrated the importance of insulin in vivo. Clinical use of insulin to moderate myelotoxicity is impractical but rosiglitazone, an insulin sensitizer, could offer hope. Although rosiglitazone tends to increase plasma insulin levels, the significant myeloprotection was partly due to direct effects on progenitors. In vitro rosiglitazone enhanced the survival of both murine progenitor and human mobilized blood stem cells in the presence of 5-fluorouracil, the effect of which was neutralized by a peroxisome-proliferator-activated receptor-γ antagonist.",
keywords = "CFU-GM (Granulocyte-macrophage progenitor cell), Insulin, Myeloprotection, Neutropenia, Rosiglitazone, Stem cell",
author = "Katayoun Djazayeri and Zolt{\'a}n Szilv{\'a}ssy and Barna Peitl and J{\'o}zsef N{\'e}meth and Laszlo Nagy and Attila Kiss and Bogl{\'a}rka Szab{\'o} and Ilona Benko",
year = "2005",
month = "10",
day = "17",
doi = "10.1016/j.ejphar.2005.08.053",
language = "English (US)",
volume = "522",
pages = "122--129",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment

AU - Djazayeri, Katayoun

AU - Szilvássy, Zoltán

AU - Peitl, Barna

AU - Németh, József

AU - Nagy, Laszlo

AU - Kiss, Attila

AU - Szabó, Boglárka

AU - Benko, Ilona

PY - 2005/10/17

Y1 - 2005/10/17

N2 - Our preliminary data indicate that rosiglitazone may be myeloprotective. We investigated whether it can modify bone marrow recovery. Five-day pre-treatment with rosiglitazone significantly accelerated recovery of 5-fluorouracil-damaged bone marrow in mice. Frequency and femoral content of granulocyte-macrophage progenitors reached mean baseline faster in pre-treated groups than in 5-fluorouracil-treated controls. Consequently, neutropenia was milder. Five-day insulin pre-treatment had similar effects in vivo. Insulin supports in vitro hematopoiesis. The observed myeloprotection demonstrated the importance of insulin in vivo. Clinical use of insulin to moderate myelotoxicity is impractical but rosiglitazone, an insulin sensitizer, could offer hope. Although rosiglitazone tends to increase plasma insulin levels, the significant myeloprotection was partly due to direct effects on progenitors. In vitro rosiglitazone enhanced the survival of both murine progenitor and human mobilized blood stem cells in the presence of 5-fluorouracil, the effect of which was neutralized by a peroxisome-proliferator-activated receptor-γ antagonist.

AB - Our preliminary data indicate that rosiglitazone may be myeloprotective. We investigated whether it can modify bone marrow recovery. Five-day pre-treatment with rosiglitazone significantly accelerated recovery of 5-fluorouracil-damaged bone marrow in mice. Frequency and femoral content of granulocyte-macrophage progenitors reached mean baseline faster in pre-treated groups than in 5-fluorouracil-treated controls. Consequently, neutropenia was milder. Five-day insulin pre-treatment had similar effects in vivo. Insulin supports in vitro hematopoiesis. The observed myeloprotection demonstrated the importance of insulin in vivo. Clinical use of insulin to moderate myelotoxicity is impractical but rosiglitazone, an insulin sensitizer, could offer hope. Although rosiglitazone tends to increase plasma insulin levels, the significant myeloprotection was partly due to direct effects on progenitors. In vitro rosiglitazone enhanced the survival of both murine progenitor and human mobilized blood stem cells in the presence of 5-fluorouracil, the effect of which was neutralized by a peroxisome-proliferator-activated receptor-γ antagonist.

KW - CFU-GM (Granulocyte-macrophage progenitor cell)

KW - Insulin

KW - Myeloprotection

KW - Neutropenia

KW - Rosiglitazone

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=26844505771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844505771&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2005.08.053

DO - 10.1016/j.ejphar.2005.08.053

M3 - Article

C2 - 16213483

AN - SCOPUS:26844505771

VL - 522

SP - 122

EP - 129

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -